BRIEF-Lilly announces positive results for three phase 3 studies of galcanezumab
May 12, 2017 at 06:48 AM EDT
* Lilly announces positive results for three phase 3 studies of galcanezumab for the prevention of episodic and chronic migraine
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.